Global Peripheral Intravenous Catheters Market Trends and Insights
Rising Burden of Chronic and Acute Diseases
Diabetes-related disability-adjusted life years climbed more than 80% since 2000, amplifying demand for dependable vascular access across acute and long-term care settings. Aging populations in the United States, Japan, and Western Europe are experiencing multi-morbidities that necessitate longer dwell catheters and higher infusion frequencies. Hospitals are validating polyurethane materials showing 52.9 MPa tensile strength yet 90% light transmittance, which improves site visualization and reduces unplanned restarts. Personalized oncology and biologic regimens demand consistent flow rates over extended durations, leading providers to favor midline and extended-dwell devices that decrease insertion trauma. Collectively, these epidemiological dynamics sustain steady volume growth and reward suppliers that bring infection-resistant, high-clarity catheters to market.Expansion of Outpatient and Home Infusion Settings
ASCs are forecast to process 44 million procedures by 2034, a 21% jump from 2024, reshaping where vascular access is initiated. Outpatient migration accelerates purchasing of devices designed for maintenance outside the ICU, including integrated extension tubing that keeps systems closed during therapy. Home infusion protocols now emphasize devices that hold patency with minimal nurse intervention, as outlined in the 2024 Infusion Therapy Standards of Practice. Digital ultrasound systems such as BD’s SiteRite 9 pair imaging with needle tracking, increasing first-attempt success rates and reducing unscheduled hospital visits. These care-delivery shifts favor suppliers that bundle catheters with portable guidance tools, consumables, and education modules for non-hospital staff.High Incidence of Catheter Failures and Complications
First-pass cannulation fails in 40% of attempts, spiking to 70% in difficult-access cohorts, adding an estimated USD 2.68 billion in emergency department costs each year in the United States. Device recalls, such as the FDA’s early alert on specific PowerPICC lots, erode clinician confidence and trigger unbudgeted replacement cycles. Central line-associated bloodstream infections still account for roughly 20% of healthcare-associated bacteremia, prompting exploration of hubs that generate on-site hypochlorous acid for continuous disinfection. Mitigating these failures requires more training, ultrasound capital, and robust data tracking, costs that smaller hospitals may struggle to absorb in the short term.Other drivers and restraints analyzed in the detailed report include:
- Regulatory Mandates on Needlestick and Blood-Exposure Safety
- Continuous Product Innovation in Catheter Materials and Design
- Environmental Sustainability and Waste-Disposal Concerns
Segment Analysis
Midline catheters generated the fastest 8.21% CAGR through 2031, even as short IV catheters retained 60.58% revenue in 2025, a position underscored by their versatility in routine infusions. Clinical trials have verified that midlines cut bloodstream infection risk relative to peripherally inserted central catheters for intermediate-duration therapies. The peripheral intravenous catheters market size for midlines is forecast to widen further as chronic-care pathways migrate to outpatient venues.Design updates center on soft-tip radiopaque shafts, integrated stabilizers, and closed connectors that remain occlusion-free longer than 28 days. Regulatory clearance for B. Braun’s Introcan Safety 2 Deep Access IV Catheter illustrates how automatic needle shielding and enhanced flow rates are converging to reinforce clinician confidence. While price-sensitive buyers still rely on basic short catheters, the clinical imperative to minimize reinsertion events positions midlines as a rising standard for oncology, heart-failure, and complex antibiotic regimens.
Safety and blood-control formats held 67.95% of 2025 revenue and are adding 8.54% CAGR, signaling that compliance is outpacing cost as the pivotal procurement criterion. Closed-hub valves and automatic retraction needles are now embedded across flagship portfolios such as BD Insyte Autoguard BC, which cuts blood exposure by 95%. The peripheral intravenous catheters market continues to phase out conventional open-hub products, especially in high-litigation regions.
Professional societies recommend pairing safety catheters with bedside ultrasound; 2024 guidelines from the American Society of Echocardiography endorse factory-integrated flashback chambers and blunt cannulae to cut insertion trauma. As hospitals track sharps-injury metrics on public dashboards, risk-adjusted reimbursement models are beginning to penalize facilities with high incident rates, reinforcing the switch to safety devices.
Complete Report Scope:
- By Product Type
- Short Peripheral IV Catheters
- Integrated / Closed IV Catheters
- Midline Catheters
- Extended-Dwell Catheters
- By Technology
- Safety / Blood-Control Catheters
- Conventional Catheters
- By Material
- Polyurethane
- Silicone
- Other Plastics
- By End User
- Hospitals
- Ambulatory Surgical Centers
- Home Healthcare & Alternate Care
- Clinics & Physician Offices
- By Application
- Medication Administration
- Fluid & Nutrition Administration
- Blood Transfusion
- Diagnostic Testing & Imaging Contrast
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America generated 39.88% of 2025 revenue, anchored by the United States, where annual consumption exceeds 300 million units. Robust reimbursement and hospital investment in safety portfolios sustain premium average selling prices. The region is adding ultrasound-guided insertion modules, remote vascular-access credentialing, and predictive analytics dashboards that monitor catheter dwell time compliance. Canada and Mexico broaden regional scale through public-sector tenders and new maquiladora manufacturing footprints, respectively.Europe, a mature regulatory environment, balances patient-safety mandates with emergent circular-economy requirements. Germany, France, and the United Kingdom account for the majority of regional demand, while Spain and Italy adopt reuse pilots to curb single-use plastics. EU Medical Device Regulation enforcement compels suppliers to refresh technical documentation and post-market surveillance, elevating market-entry barriers for new entrants. Public procurement frameworks now weight sustainability alongside clinical evidence, fostering dialogue on recycled polymers and extended-life formats.
Asia-Pacific is the fastest-growing geography at 7.34% CAGR, driven by China, India, Japan, South Korea, and Australia. India’s medical technology sector is set to scale from USD 16-17 billion to USD 50 billion by 2030 under the New Drugs, Medical Devices and Cosmetics Bill of 2023, catalyzing domestic manufacturing alliances. China leverages cost-effective mass production yet is investing in premium image-guided systems to serve tertiary hospitals. Japan’s super-aged society necessitates advanced silicone designs for fragile veins, while Australia focuses on infection-prevention benchmarks that align with national quality indicators. Collectively, these trends expand the peripheral intravenous catheters market footprint across price tiers, compelling multinationals to localize supply chains and co-develop clinical education platforms.
List of Companies Covered in this Report:
- Becton Dickinson & Co.
- B. Braun
- ICU Medical
- Teleflex
- Terumo Corp.
- Nipro Medical Corp.
- Vygon
- VOGT Medical GmbH
- Lineus Medical
- Access Vascular Inc.
- AngioDynamics
- 3M
- Baxter
- MedSource Labs
- RenovoRx
- Retractable Technologies
- Vascular Pathways Inc.
- Health Line Medical Products
- Shenzhen Antmed Co. Ltd.
- Greiner Bio-One GmbH
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Becton Dickinson & Co.
- B. Braun Melsungen AG
- ICU Medical Inc. (Smiths Medical)
- Teleflex Inc.
- Terumo Corp.
- Nipro Medical Corp.
- Vygon SA
- VOGT Medical GmbH
- Lineus Medical
- Access Vascular Inc.
- AngioDynamics Inc.
- 3M Company
- Baxter International Inc.
- MedSource Labs
- RenovoRx Inc.
- Retractable Technologies Inc.
- Vascular Pathways Inc.
- Health Line Medical Products
- Shenzhen Antmed Co. Ltd.
- Greiner Bio-One GmbH

